The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Blood Plasma Fractionation Market Research Report 2025
Synopsis
Human blood plasma is nature's raw material for dozens of life-saving treatments and medications. By extracting the active ingredients and disinfection, people get related preparations from blood plasma, which is called Blood Plasma Fractionation.
The global Blood Plasma Fractionation market was valued at US$ 28320 million in 2023 and is anticipated to reach US$ 47160 million by 2030, witnessing a CAGR of 7.6% during the forecast period 2024-2030.
Global key blood plasma fractionation players include CSL, Grifols and Takeda etc. The top 3 companies hold a share about 55%. North America is the largest market with a share about 40%, followed by Asia-Pacific and Europe.
In terms of product, Immune Globulin is the largest segment with a share about 50%. And in terms of applications, the largest application is hospital with a share about 70%.
This report aims to provide a comprehensive presentation of the global market for Blood Plasma Fractionation, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Blood Plasma Fractionation.
Report Scope
The Blood Plasma Fractionation market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Blood Plasma Fractionation market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Blood Plasma Fractionation manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Takeda
CSL
Grifols
Octapharma
Kedrion
LFB Group
Biotest
BPL
RAAS
CBPO
Hualan Bio
Tiantan Bio
Shuanglin Bio
Boya Bio
Yuanda Shuyang
Weiguang Bio
Nanyue Bio
KM Biologics
Segment by Type
Immune Globulin
Coagulation Factor
Albumin
Other
Segment by Application
Hospital
Retail Pharmacy
Other
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Blood Plasma Fractionation manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Blood Plasma Fractionation in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Human blood plasma is nature's raw material for dozens of life-saving treatments and medications. By extracting the active ingredients and disinfection, people get related preparations from blood plasma, which is called Blood Plasma Fractionation.
The global Blood Plasma Fractionation market was valued at US$ 28320 million in 2023 and is anticipated to reach US$ 47160 million by 2030, witnessing a CAGR of 7.6% during the forecast period 2024-2030.
Global key blood plasma fractionation players include CSL, Grifols and Takeda etc. The top 3 companies hold a share about 55%. North America is the largest market with a share about 40%, followed by Asia-Pacific and Europe.
In terms of product, Immune Globulin is the largest segment with a share about 50%. And in terms of applications, the largest application is hospital with a share about 70%.
This report aims to provide a comprehensive presentation of the global market for Blood Plasma Fractionation, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Blood Plasma Fractionation.
Report Scope
The Blood Plasma Fractionation market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Blood Plasma Fractionation market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Blood Plasma Fractionation manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Takeda
CSL
Grifols
Octapharma
Kedrion
LFB Group
Biotest
BPL
RAAS
CBPO
Hualan Bio
Tiantan Bio
Shuanglin Bio
Boya Bio
Yuanda Shuyang
Weiguang Bio
Nanyue Bio
KM Biologics
Segment by Type
Immune Globulin
Coagulation Factor
Albumin
Other
Segment by Application
Hospital
Retail Pharmacy
Other
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Blood Plasma Fractionation manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Blood Plasma Fractionation in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Index1 Blood Plasma Fractionation Market Overview
1.1 Product Overview and Scope of Blood Plasma Fractionation
1.2 Blood Plasma Fractionation Segment by Type
1.2.1 Global Blood Plasma Fractionation Market Value Comparison by Type (2024-2030)
1.2.2 Immune Globulin
1.2.3 Coagulation Factor
1.2.4 Albumin
1.2.5 Other
1.3 Blood Plasma Fractionation Segment by Application
1.3.1 Global Blood Plasma Fractionation Market Value by Application: (2024-2030)
1.3.2 Hospital
1.3.3 Retail Pharmacy
1.3.4 Other
1.4 Global Blood Plasma Fractionation Market Size Estimates and Forecasts
1.4.1 Global Blood Plasma Fractionation Revenue 2019-2030
1.4.2 Global Blood Plasma Fractionation Sales 2019-2030
1.4.3 Global Blood Plasma Fractionation Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Blood Plasma Fractionation Market Competition by Manufacturers
2.1 Global Blood Plasma Fractionation Sales Market Share by Manufacturers (2019-2024)
2.2 Global Blood Plasma Fractionation Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Blood Plasma Fractionation Average Price by Manufacturers (2019-2024)
2.4 Global Blood Plasma Fractionation Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Blood Plasma Fractionation, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Blood Plasma Fractionation, Product Type & Application
2.7 Blood Plasma Fractionation Market Competitive Situation and Trends
2.7.1 Blood Plasma Fractionation Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Blood Plasma Fractionation Players Market Share by Revenue
2.7.3 Global Blood Plasma Fractionation Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Blood Plasma Fractionation Retrospective Market Scenario by Region
3.1 Global Blood Plasma Fractionation Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Blood Plasma Fractionation Global Blood Plasma Fractionation Sales by Region: 2019-2030
3.2.1 Global Blood Plasma Fractionation Sales by Region: 2019-2024
3.2.2 Global Blood Plasma Fractionation Sales by Region: 2025-2030
3.3 Global Blood Plasma Fractionation Global Blood Plasma Fractionation Revenue by Region: 2019-2030
3.3.1 Global Blood Plasma Fractionation Revenue by Region: 2019-2024
3.3.2 Global Blood Plasma Fractionation Revenue by Region: 2025-2030
3.4 North America Blood Plasma Fractionation Market Facts & Figures by Country
3.4.1 North America Blood Plasma Fractionation Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Blood Plasma Fractionation Sales by Country (2019-2030)
3.4.3 North America Blood Plasma Fractionation Revenue by Country (2019-2030)
3.4.4 United States
3.4.5 Canada
3.5 Europe Blood Plasma Fractionation Market Facts & Figures by Country
3.5.1 Europe Blood Plasma Fractionation Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Blood Plasma Fractionation Sales by Country (2019-2030)
3.5.3 Europe Blood Plasma Fractionation Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Blood Plasma Fractionation Market Facts & Figures by Country
3.6.1 Asia Pacific Blood Plasma Fractionation Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Blood Plasma Fractionation Sales by Country (2019-2030)
3.6.3 Asia Pacific Blood Plasma Fractionation Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.7 Latin America Blood Plasma Fractionation Market Facts & Figures by Country
3.7.1 Latin America Blood Plasma Fractionation Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Blood Plasma Fractionation Sales by Country (2019-2030)
3.7.3 Latin America Blood Plasma Fractionation Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Blood Plasma Fractionation Market Facts & Figures by Country
3.8.1 Middle East and Africa Blood Plasma Fractionation Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Blood Plasma Fractionation Sales by Country (2019-2030)
3.8.3 Middle East and Africa Blood Plasma Fractionation Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Blood Plasma Fractionation Sales by Type (2019-2030)
4.1.1 Global Blood Plasma Fractionation Sales by Type (2019-2024)
4.1.2 Global Blood Plasma Fractionation Sales by Type (2025-2030)
4.1.3 Global Blood Plasma Fractionation Sales Market Share by Type (2019-2030)
4.2 Global Blood Plasma Fractionation Revenue by Type (2019-2030)
4.2.1 Global Blood Plasma Fractionation Revenue by Type (2019-2024)
4.2.2 Global Blood Plasma Fractionation Revenue by Type (2025-2030)
4.2.3 Global Blood Plasma Fractionation Revenue Market Share by Type (2019-2030)
4.3 Global Blood Plasma Fractionation Price by Type (2019-2030)
5 Segment by Application
5.1 Global Blood Plasma Fractionation Sales by Application (2019-2030)
5.1.1 Global Blood Plasma Fractionation Sales by Application (2019-2024)
5.1.2 Global Blood Plasma Fractionation Sales by Application (2025-2030)
5.1.3 Global Blood Plasma Fractionation Sales Market Share by Application (2019-2030)
5.2 Global Blood Plasma Fractionation Revenue by Application (2019-2030)
5.2.1 Global Blood Plasma Fractionation Revenue by Application (2019-2024)
5.2.2 Global Blood Plasma Fractionation Revenue by Application (2025-2030)
5.2.3 Global Blood Plasma Fractionation Revenue Market Share by Application (2019-2030)
5.3 Global Blood Plasma Fractionation Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Takeda
6.1.1 Takeda Corporation Information
6.1.2 Takeda Description and Business Overview
6.1.3 Takeda Blood Plasma Fractionation Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Takeda Blood Plasma Fractionation Product Portfolio
6.1.5 Takeda Recent Developments/Updates
6.2 CSL
6.2.1 CSL Corporation Information
6.2.2 CSL Description and Business Overview
6.2.3 CSL Blood Plasma Fractionation Sales, Revenue and Gross Margin (2019-2024)
6.2.4 CSL Blood Plasma Fractionation Product Portfolio
6.2.5 CSL Recent Developments/Updates
6.3 Grifols
6.3.1 Grifols Corporation Information
6.3.2 Grifols Description and Business Overview
6.3.3 Grifols Blood Plasma Fractionation Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Grifols Blood Plasma Fractionation Product Portfolio
6.3.5 Grifols Recent Developments/Updates
6.4 Octapharma
6.4.1 Octapharma Corporation Information
6.4.2 Octapharma Description and Business Overview
6.4.3 Octapharma Blood Plasma Fractionation Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Octapharma Blood Plasma Fractionation Product Portfolio
6.4.5 Octapharma Recent Developments/Updates
6.5 Kedrion
6.5.1 Kedrion Corporation Information
6.5.2 Kedrion Description and Business Overview
6.5.3 Kedrion Blood Plasma Fractionation Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Kedrion Blood Plasma Fractionation Product Portfolio
6.5.5 Kedrion Recent Developments/Updates
6.6 LFB Group
6.6.1 LFB Group Corporation Information
6.6.2 LFB Group Description and Business Overview
6.6.3 LFB Group Blood Plasma Fractionation Sales, Revenue and Gross Margin (2019-2024)
6.6.4 LFB Group Blood Plasma Fractionation Product Portfolio
6.6.5 LFB Group Recent Developments/Updates
6.7 Biotest
6.6.1 Biotest Corporation Information
6.6.2 Biotest Description and Business Overview
6.6.3 Biotest Blood Plasma Fractionation Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Biotest Blood Plasma Fractionation Product Portfolio
6.7.5 Biotest Recent Developments/Updates
6.8 BPL
6.8.1 BPL Corporation Information
6.8.2 BPL Description and Business Overview
6.8.3 BPL Blood Plasma Fractionation Sales, Revenue and Gross Margin (2019-2024)
6.8.4 BPL Blood Plasma Fractionation Product Portfolio
6.8.5 BPL Recent Developments/Updates
6.9 RAAS
6.9.1 RAAS Corporation Information
6.9.2 RAAS Description and Business Overview
6.9.3 RAAS Blood Plasma Fractionation Sales, Revenue and Gross Margin (2019-2024)
6.9.4 RAAS Blood Plasma Fractionation Product Portfolio
6.9.5 RAAS Recent Developments/Updates
6.10 CBPO
6.10.1 CBPO Corporation Information
6.10.2 CBPO Description and Business Overview
6.10.3 CBPO Blood Plasma Fractionation Sales, Revenue and Gross Margin (2019-2024)
6.10.4 CBPO Blood Plasma Fractionation Product Portfolio
6.10.5 CBPO Recent Developments/Updates
6.11 Hualan Bio
6.11.1 Hualan Bio Corporation Information
6.11.2 Hualan Bio Blood Plasma Fractionation Description and Business Overview
6.11.3 Hualan Bio Blood Plasma Fractionation Sales, Revenue and Gross Margin (2019-2024)
6.11.4 Hualan Bio Blood Plasma Fractionation Product Portfolio
6.11.5 Hualan Bio Recent Developments/Updates
6.12 Tiantan Bio
6.12.1 Tiantan Bio Corporation Information
6.12.2 Tiantan Bio Blood Plasma Fractionation Description and Business Overview
6.12.3 Tiantan Bio Blood Plasma Fractionation Sales, Revenue and Gross Margin (2019-2024)
6.12.4 Tiantan Bio Blood Plasma Fractionation Product Portfolio
6.12.5 Tiantan Bio Recent Developments/Updates
6.13 Shuanglin Bio
6.13.1 Shuanglin Bio Corporation Information
6.13.2 Shuanglin Bio Blood Plasma Fractionation Description and Business Overview
6.13.3 Shuanglin Bio Blood Plasma Fractionation Sales, Revenue and Gross Margin (2019-2024)
6.13.4 Shuanglin Bio Blood Plasma Fractionation Product Portfolio
6.13.5 Shuanglin Bio Recent Developments/Updates
6.14 Boya Bio
6.14.1 Boya Bio Corporation Information
6.14.2 Boya Bio Blood Plasma Fractionation Description and Business Overview
6.14.3 Boya Bio Blood Plasma Fractionation Sales, Revenue and Gross Margin (2019-2024)
6.14.4 Boya Bio Blood Plasma Fractionation Product Portfolio
6.14.5 Boya Bio Recent Developments/Updates
6.15 Yuanda Shuyang
6.15.1 Yuanda Shuyang Corporation Information
6.15.2 Yuanda Shuyang Blood Plasma Fractionation Description and Business Overview
6.15.3 Yuanda Shuyang Blood Plasma Fractionation Sales, Revenue and Gross Margin (2019-2024)
6.15.4 Yuanda Shuyang Blood Plasma Fractionation Product Portfolio
6.15.5 Yuanda Shuyang Recent Developments/Updates
6.16 Weiguang Bio
6.16.1 Weiguang Bio Corporation Information
6.16.2 Weiguang Bio Blood Plasma Fractionation Description and Business Overview
6.16.3 Weiguang Bio Blood Plasma Fractionation Sales, Revenue and Gross Margin (2019-2024)
6.16.4 Weiguang Bio Blood Plasma Fractionation Product Portfolio
6.16.5 Weiguang Bio Recent Developments/Updates
6.17 Nanyue Bio
6.17.1 Nanyue Bio Corporation Information
6.17.2 Nanyue Bio Blood Plasma Fractionation Description and Business Overview
6.17.3 Nanyue Bio Blood Plasma Fractionation Sales, Revenue and Gross Margin (2019-2024)
6.17.4 Nanyue Bio Blood Plasma Fractionation Product Portfolio
6.17.5 Nanyue Bio Recent Developments/Updates
6.18 KM Biologics
6.18.1 KM Biologics Corporation Information
6.18.2 KM Biologics Blood Plasma Fractionation Description and Business Overview
6.18.3 KM Biologics Blood Plasma Fractionation Sales, Revenue and Gross Margin (2019-2024)
6.18.4 KM Biologics Blood Plasma Fractionation Product Portfolio
6.18.5 KM Biologics Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Blood Plasma Fractionation Industry Chain Analysis
7.2 Blood Plasma Fractionation Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Blood Plasma Fractionation Production Mode & Process
7.4 Blood Plasma Fractionation Sales and Marketing
7.4.1 Blood Plasma Fractionation Sales Channels
7.4.2 Blood Plasma Fractionation Distributors
7.5 Blood Plasma Fractionation Customers
8 Blood Plasma Fractionation Market Dynamics
8.1 Blood Plasma Fractionation Industry Trends
8.2 Blood Plasma Fractionation Market Drivers
8.3 Blood Plasma Fractionation Market Challenges
8.4 Blood Plasma Fractionation Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
